跳至主要内容
临床试验/EUCTR2014-002509-39-GB
EUCTR2014-002509-39-GB进行中(未招募)1 期

Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics - PEAce (Patient Education on Acne)

GALDERMA R&D0 个研究点目标入组 97 人开始时间: 2014年9月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
GALDERMA R&D
入组人数
97

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • 1.Male or female subjects age of 12 years or older,
  • 2.With facial acne vulgaris that can be managed in primary care,
  • 3.Female subjects of childbearing potential with a negative urine pregnancy test (UPT) at Baseline visit,
  • 4.Female subjects of childbearing potential must practice a highly effective method of contraception during the study: medical contraception (combined oral contraceptives [estrogens and progesterone] or implanted or injectable contraceptives with stable dose for at least 1 month prior to study entry), bilateral tubal ligation, hormonal intrauterine device (inserted at least 1 month prior to study entry), strict abstinence (at least 1 month prior to study entry and agree to continue for the duration of the study), or vasectomized partner (at least 3 months prior to study entry),
  • 5.Females of non-childbearing potential, e.g., premenses, post-menopausal (absence of menstrual bleeding for 1 year prior to study entry), hysterectomy, or bilateral ovariectomy,
  • 6.Subjects willing and capable of complying with the extent and degree required by the protocol,
  • 7.Subjects or the parents/legal guardians (for subjects of 12-17 years old) understand and sign the Informed Consent Form (ICF) at Baseline, prior to any investigational procedure being performed.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 70
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Female subjects who are pregnant, nursing or planning a pregnancy during the study,
  • 2.Subjects have acne on their chest and/or back,
  • 3.Subjects have a very severe variant of acne such as fulminating acne with systemic symptoms (acne fulminans),
  • 4.Subjects with severe acne or painful, deep nodules or cysts (nodulocystic acne),
  • 5.Subjects with severe social or psychological problems including a morbid fear of deformity (dysmorphophobia),
  • 6.Subjects are at risk of, or are developing, scarring despite primary care therapies,
  • 7.Subjects have moderate acne that has failed to respond to treatment which should generally include several courses of both topical and systemic treatment over a period of at least 6 months,
  • 8.Subjects are suspected of having an underlying endocrinological cause for the acne (such as polycystic ovary syndrome) that needs assessment,
  • 9.Subjects currently taking any other acne treatments,
  • 10.Subjects with known impaired hepatic or renal functions
  • 11.Subjects with known intolerance to lactose,
  • 12.Subjects with a condition or who are in a situation which, in the investigator’s opinion, may put the subject at risk, confound the study results, or interfere with the subject’s participation in the study,
  • 13.Subjects who are at risk in terms of precautions, warnings, and contraindications (see package inserts),
  • 14.Subjects with known or suspected allergies or sensitivities to any component of the study drug (see package inserts),
  • 15.Subjects who have participated in another investigational drug or device research study within 30 days of enrolment of this study,
  • 16.Subjects of 12-17 years for whom the signed ICF from their parents/legal guardians is not obtained,
  • 17.Subjects under guardianship, hospitalised subjects in a public or private institution for a reason other than the research, and subjects deprived of their freedom

研究者

发起方
GALDERMA R&D

相似试验

Patient Education on Acne | 临床试验